XERS
- Xeris Biopharma Holdings, Inc.
()
Overview
Company Summary
Xeris Biopharma Holdings, Inc. (XERS) is a pharmaceutical company specializing in the development and commercialization of innovative injectable and infusible drug formulations. They focus on creating alternative delivery systems for existing drugs to enhance patient experience and improve treatment outcomes.
Xeris Biopharma employs a proprietary formulation technology called XeriSol� that enables the solubility of drugs that are traditionally insoluble, unstable, or difficult to administer. This technology aims to make drug delivery more convenient, effective, and safe, as well as to reduce the complexity associated with drug administration for patients and healthcare providers.
The company primarily operates in two areas: diabetes and therapeutic rescue. In the diabetes field, Xeris Biopharma is focused on developing and commercializing ready-to-use, room temperature-stable glucagon rescue products. Glucagon is a hormone used to treat severe hypoglycemia (low blood sugar) in people with diabetes. Xeris' glucagon formulations can be administered via injection or nasal spray, providing an alternative to the traditional glucagon emergency kits that require reconstitution.
In the therapeutic rescue area, Xeris Biopharma is working on developing and commercializing novel formulations of approved drugs. These formulations aim to address specific challenges with existing treatments, such as stability, ease of administration, and patient compliance. By improving the delivery of these drugs, Xeris aims to provide better treatment options in areas such as central nervous system conditions, seizure management, and autoimmune diseases.
Overall, Xeris Biopharma Holdings, Inc. is committed to advancing patient care by developing innovative drug delivery solutions that improve the convenience, safety, and effectiveness of therapeutic treatments.